stockrowLatest quarter
Roivant reported Q1 FY2027 revenue of $1.4 million, below the consensus of $2.2 million. Adjusted EPS was −$0.33, matching the consensus of −$0.33.
Revenue fell from $2.2 million a year earlier, while diluted EPS was −$0.26, compared with −$0.33. Roivant’s gross margin was 80.3%, down from 92.9% a year earlier.
The company’s filing shows research and development expenses rose to $202.0 million from $152.9 million, primarily as program-specific costs increased. Roivant attributed much of that increase to work on its anti-FcRn franchise and mosliciguat. General and administrative expenses rose to $165.5 million from $134.0 million, primarily because of higher personnel costs, including employee bonuses related to the Moderna settlement.
Free cash flow was −$270.9 million, compared with −$208.4 million a year earlier. The filing said operating cash used rose to $270.5 million from $204.4 million, primarily reflecting spending on research programs, commercial-readiness activities for brepocitinib and higher income tax payments.
| Q1 FY2027 | Q1 FY2026 | Change | |
|---|---|---|---|
| Revenue | $1.4 million | $2.2 million | −33.5% |
| Diluted EPS | −$0.26 | −$0.33 | — |
| Gross margin | 80.3% | 92.9% | −12.6 percentage points |
| Operating margin | −25,380.9% | −13,130.0% | −12250.9 percentage points |
| Free cash flow | −$270.9 million | −$208.4 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$0.33 | −$0.33 | In line |
| Revenue | $1.4 million | $2.2 million | Missed by 35.4% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
Roivant’s latest earnings call was not available for review, so management’s remarks and its discussion with analysts could not be assessed.
Guidance
Roivant’s management guidance was not available for review, so the company’s current outlook and any changes from its previous guidance could not be compared here.